Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Overall
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(64)
•••
Comment by SpaceLabson Nov 23, 2021 7:23pm
266 Views
Post# 34159462

RE:Overall

RE:Overall
Alex1726 wrote:
I think Xortx should get the ODD for xrx-008,  after all the FDA has nothing to loose and probably also a special protocol for XRX-001 because of covid but Madoff needs to move his a.... ss


MADOFF CEO of Xortx is a Disaster from Day 1 when he CHOSE and he was taken for a RIDE by the RoadRunner FUND MANAGERS in NY, Boston and Calgary 40th. [ab42 SHARK in it]

What SHAREHOLDERS are struggling today is a WASHOUT of shr value and MAD'OFF only managed to raise US$12M in the 1st IPO, I call this Dr. IPO and not a CEO IPO on NASDAQ.

RoadRunner Financiers have FULL CONTROL of Dr. MAD'OFF CEO and they will get this DELISTED from NASDAQ very, very SOON.
AGM is about more ROLLBACKS, Allen CEO, pls STEP DOWN Now !!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities